Allogene Therapeutics, Inc. — Investor Relations & Filings
Filings indexed
523
across all filing types
Latest filing
2026-05-28
Proxy Solicitation & In…
Country
US
United States of America
Listing
US
ALLO
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies. The company engineers T cells from healthy donors to create "off-the-shelf" treatments for cancer and autoimmune diseases. This approach is designed to enable on-demand availability, scalability, and reliability, contrasting with autologous therapies that use a patient's own cells. Allogene's pipeline utilizes multiplex gene-engineering and gene-editing capabilities. Its key investigational programs include cemacabtagene ansegedleucel (cema-cel) for large B-cell lymphoma, ALLO-316 for clear cell renal cell carcinoma, and ALLO-329 for autoimmune disease.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| DEFA14A | 2026-05-28 | English | |
| 8-K | 2026-05-28 | English | |
| DEFA14A | 2026-05-20 | English | |
| 8-K - Allogene Therapeutics, Inc. (0001737287) (Filer) | 2026-05-13 | English | |
| 424B5 - Allogene Therapeutics, Inc. (0001737287) (Filer) | 2026-04-15 | English | |
| 424B5 - Allogene Therapeutics, Inc. (0001737287) (Filer) | 2026-04-13 | English |
Browse filings by year
9 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 47868448 | DEFA14A | 2026-05-28 | English | ||
| 47868481 | 8-K | 2026-05-28 | English | ||
| 46726629 | DEFA14A | 2026-05-20 | English | ||
| 45762022 | 8-K - Allogene Therapeutics, Inc. (0001737287) (Filer) | 2026-05-13 | English | ||
| 34609865 | 424B5 - Allogene Therapeutics, Inc. (0001737287) (Filer) | 2026-04-15 | English | ||
| 34439500 | 424B5 - Allogene Therapeutics, Inc. (0001737287) (Filer) | 2026-04-13 | English | ||
| 34434910 | 8-K - Allogene Therapeutics, Inc. (0001737287) (Filer) | 2026-04-13 | English | ||
| 34409554 | 8-K - Allogene Therapeutics, Inc. (0001737287) (Filer) | 2026-04-13 | English | ||
| 32897513 | 4 - ALLOGENE THERAPEUTICS, INC. (0001737287) (Filer) | 2026-03-04 | English | ||
| 31528502 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 31528553 | 4 Filing | 2026-02-04 | English | ||
| 31528550 | 4 Filing | 2026-02-04 | English | ||
| 31528532 | 4 Filing | 2026-02-04 | English | ||
| 31528520 | 4 Filing | 2026-02-04 | English | ||
| 31528515 | 4 Filing | 2026-02-04 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
HINOVA PHARMACEUTICALS INC.
Clinical-stage developer of cancer and metabolic disease sm…
|
688302 | CN | Manufacturing |
|
Hin Sang Group (International) Holding Co. Ltd.
Develops and distributes children's healthcare, TCM, person…
|
6893 | HK | Manufacturing |
|
HISAMITSU PHARMACEUTICAL CO.,INC.
A pharmaceutical firm specializing in external pain relief …
|
4530 | JP | Manufacturing |
|
HK inno.N Corporation
A biohealth company developing pharmaceuticals and consumer…
|
195940 | KR | Manufacturing |
|
HLB Genex, Inc.
Develops and produces customized enzyme and microbiome-base…
|
187420 | KR | Manufacturing |
|
HLB INC.
A biopharmaceutical company developing new global anti-canc…
|
028300 | KR | Manufacturing |
|
HLB Life Science CO.,LTD.
Develops anti-cancer drugs and manufactures in vitro diagno…
|
067630 | KR | Manufacturing |
|
HLB Pep Co., Ltd.
Biopharmaceutical firm specializing in peptide-based drug R…
|
196300 | KR | Manufacturing |
|
HLB PHARMACEUTICAL CO., LTD.
Develops and manufactures pharmaceuticals, quasi-drugs, and…
|
047920 | KR | Manufacturing |
|
HLB Therapeutics Co.,Ltd.
Biopharmaceutical firm developing drugs for rare diseases i…
|
115450 | KR | Manufacturing |
Allogene Therapeutics, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/33378/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=33378 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=33378 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=33378 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 33378}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Allogene Therapeutics, Inc. (id: 33378)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.